Skip to main content
Suzhou Zelgen Biopharmaceuticals Co., Ltd. logo

Suzhou Zelgen Biopharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 688266 ISIN · CNE100003RP1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 722 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688266

About Suzhou Zelgen Biopharmaceuticals Co., Ltd.

https://www.zelgen.com/en/

Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule and therapeutic protein drugs. The company maintains a diverse pipeline targeting oncology, hematology, liver diseases, and autoimmune disorders. Its core technology platforms include a precision medicine-driven drug discovery engine and a recombinant protein production system. A key commercialized product is donafenib tosylate, a multi-kinase inhibitor indicated for the treatment of advanced hepatocellular carcinoma. Zelgen's research and development efforts emphasize the creation of first-in-class and best-in-class therapies to address unmet medical needs. The pipeline includes various candidates in clinical stages, such as recombinant human thrombin for surgical hemostasis and JAK inhibitors for inflammatory conditions.

Recent filings

Filing Released Lang Actions
泽璟制药关于自愿披露注射用人促甲状腺素β III期临床试验达到预设主要终点的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Suzhou Zelgen Biopharmaceutical Co., Ltd. regarding the voluntary disclosure that the Phase III clinical trial of their drug injection for human thyroid-stimulating hormone beta has reached the preset primary endpoint. It discusses clinical trial results, future regulatory submission plans to the National Medical Products Administration (NMPA) in China, and risk warnings. The document does not contain financial statements or detailed financial performance data. It is a regulatory announcement about clinical trial progress and drug development status, not a financial report or earnings release. The document length is 2285 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2026-05-07 Chinese
泽璟制药股东及董事、高级管理人员减持股份结果公告
Director's Dealing Classification · 89% confidence The document is an announcement by Suzhou Zelgen Biopharmaceutical Co., Ltd. disclosing the completion of share reduction transactions by its controlling shareholder, actual controllers, director, and senior management. It details insider sales volumes, shareholding changes, sale dates, price ranges, and compliance statements. This falls under insider/share transactions by directors and executives rather than a company buyback or general regulatory notice. Therefore, it matches the “Director's Dealing” category.
2026-04-17 Chinese
泽璟制药2025年度独立董事述职报告（郭冰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025, detailing the independent director's activities, attendance, and observations during their term. It includes information about board meetings, communication with shareholders, and other governance-related activities. The content focuses on the independent director's duties and compliance with relevant laws and company regulations. It does not contain financial statements or audit results, nor is it a general management report or earnings release. It is a specific report related to board/management information, particularly about the independent director's role and performance. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 2433 characters, which is sufficient for a detailed report but not a full annual report or audit report. Confidence is high due to clear focus on director duties and governance.
2026-03-27 Chinese
信永中和会计师事务所（特殊普通合伙）出具的苏州泽璟生物制药股份有限公司2025年12月31日内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled “内部控制审计报告” (Internal Control Audit Report) for the fiscal period ending December 31, 2025, issued by a certified public accounting firm. It contains the auditor’s responsibilities, scope, opinion on the effectiveness of financial reporting internal controls, and detailed audit content. It is a standalone audit report on internal controls rather than a full annual report or simple announcement, matching the definition for Audit Report / Information (AR). FY 2025
2026-03-27 Chinese
泽璟制药2025年度独立董事述职报告（RUYIHE（何如意）-已离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025, detailing the independent director's attendance, duties, and evaluations during their term. It includes information about board meetings, committee participation, communication with shareholders, and opinions on company governance and financial reporting. The content focuses on the independent director's role and activities rather than financial results or audit opinions. This type of report is a detailed management or governance-related report about board activities and director responsibilities, not an annual report, audit report, or earnings release. It is not a short announcement or certification but a substantive report on director duties and governance. Therefore, the most appropriate classification is Board/Management Information (MANG).
2026-03-27 Chinese
泽璟制药2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage, management, and actual use of funds raised by Suzhou Zelgen Biopharmaceutical Co., Ltd. for the fiscal year 2025. It includes specifics on the amounts raised through initial public offerings and private placements, the timing of fund receipt, usage details, cash management, regulatory compliance, and auditor and sponsor opinions. The document references regulatory approvals, audit verification reports, and compliance with listing rules. It is not a general annual report or earnings release but a specialized report focused on the use of raised capital. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length and content confirm it is the report itself, not just an announcement of a report. Therefore, the correct classification is CAP.
2026-03-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.